EWA
TVTX icon

EverSource Wealth Advisors’s Travere Therapeutics TVTX Stock Holding History

EverSource Wealth Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.4K Buy
236
+15
+7% +$665 ﹤0.01% 2719
2026
Q1 		$6.57K Sell
221
-10
-4% -$299 ﹤0.01% 3132
2025
Q4 		$8.83K Buy
231
+117
+103% +$3.8K ﹤0.01% 2863
2025
Q3 		$2.73K Buy
114
+81
+245% +$1.52K ﹤0.01% 3408
2025
Q2 		$489 Sell
33
-271
-89% -$4.49K ﹤0.01% 3906
2025
Q1 		$5.45K Buy
304
+157
+107% +$3.19K ﹤0.01% 2453
2024
Q4 		$2.56K Buy
+147
New +$2.6K ﹤0.01% 2623

Other funds holding TVTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BC
Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
HCMT
Highland Capital Management (Tennessee) Memphis, Tennessee $2.17B AUM 54.74% 1-Year Est. Return

EverSource Wealth Advisors's TVTX Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Travere Therapeutics (TVTX) stake by 6.8% in Q2 2026, buying an estimated $665 and bringing the position to 236 shares worth $13.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2719.

EverSource Wealth Advisors first reported a position in TVTX in Q4 2024 and has held it in 7 quarters since. 35 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • EverSource Wealth Advisors held 236 shares of Travere Therapeutics worth $13.4K as of Q2 2026.
  • EverSource Wealth Advisors bought 15 Travere Therapeutics shares in Q2 2026, an estimated $665.
  • Travere Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #2719 holding.
  • EverSource Wealth Advisors first reported a position in Travere Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 35 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.